Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
Volume 4.21M
Average 2.11M
Returns on capital
Beam Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-6.5%
avg -21.1%
ROIC
-27.4%
avg -0.0%
ROA
-5.4%
avg -69.0%
Analysis
ROA is currently the strongest return metric at -5.4% versus its period average of -69.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
John Evans | Chief Executive Officer & Director | USD 1.43M | 48 | — | — |
Sravan Kumar Emany | Chief Financial Officer | USD 1.3M | 48 | 105.46K | 0.10% |
Giuseppe Ciaramella | President | USD 1.18M | 57 | 130.50K | 0.13% |
Amy Simon | Chief Medical Officer | USD 897.69K | 61 | 85.70K | 0.08% |
Christine Bellon | Chief Legal Officer & Corporate Secretary | USD 834.19K | 60 | 109.71K | 0.11% |
David R. Liu | Co-Founder | — | — | — | — |
Feng Zhang | Co-Founder | — | — | — | — |
Manmohan Singh | Chief Technology Officer | — | — | — | — |
Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer | — | — | 50.98K | 0.05% |
J. Keith Joung | Co-Founder | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
31
$19.74M
Net Transaction Value
−$19.74M
Net selling
Most Active
Evans John M.
13 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 16, 26Oct 16, 2026 | Evans John M. Direct | Sell | $599.6K$599,595.00 |
| Oct 15, 26Oct 15, 2026 | Evans John M. Direct | Sell | $589.2K$589,150.00 |
| Oct 1, 26Oct 1, 2026 | Cavanagh Bethany J Direct | Sell | $4.6K$4,564.67 |
| Jul 27, 26Jul 27, 2026 | Simon Amy Direct | Sell | $429K$429,036.91 |
| Jun 30, 26Jun 30, 2026 | Simon Amy Direct | Sell | $13K$12,954.29 |
| Jun 30, 26Jun 30, 2026 | Evans John M. Direct | Sell | $791.5K$791,482.23 |
| Jun 30, 26Jun 30, 2026 | Evans John M. Direct | Sell | $66.2K$66,203.03 |
| Jun 29, 26Jun 29, 2026 | Evans John M. Direct | Sell | $471.5K$471,528.05 |
| Jun 29, 26Jun 29, 2026 | Evans John M. Direct | Sell | $415.8K$415,823.89 |
| Jun 26, 26Jun 26, 2026 | FMR LLC Indirect | Sell | $8.9M$8,867,466.88 |
1–10 of 31
Summary
Insiders reported 0 buys worth $0.00 and 31 sells worth $19.74M over the last 12 months. That adds up to net selling of $19.74M. Evans John M. was the most active insider with 13 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +31.9% | +33.5% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +31.9% over three years. Forward estimates point to Revenue at +33.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Beam Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about BEAM's management, answered from reported figures.
Who manages BEAM?
Beam Therapeutics Inc. (BEAM) lists 10 active executives. The top listed executive is Amy Simon, Chief Medical Officer.
Are BEAM insiders buying or selling?
Recent insider activity shows net selling of $12.99M.
Continue the stock analysis
Jump to another research area for this company.